Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis

S. A. Vinores, J. R. Perez-Polo

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The sensitivity of the rat nervous system to malignant transformation by ethylnitrosourea (ENU) is a function of age at treatment. From late gestation, nervous structures decrease in sensitivity with age as non-neural structures increase in susceptibility. There is a decrease in the proportion of neural tumors induced by ENU and an increase in survival time when nerve growth factor (NGF) levels are elevated in the fetal or neonatal stage. If antibodies directed against mouse beta-NGF (anti-NGF) are administered prior to neonatal ENU treatment, neural tumors appear earlier, although in the same proportion as with treatment by ENU alone. This effect is not observed if the ENU is administered first. This phenomenon seems to be attributed to an increased number of trigeminal nerve neurinomas, which have a shorter latent period than other nervous system tumors. The induced neurological tumors in rats treated neonatally with anti-NGF prior to ENU seem to be almost exclusively neurinomas in the peripheral nervous system. Fetal anti-NGF treatment leads to an increased number of intracerebral gliomas and a longer survival time, which corresponds to the longer latent period of these tumors. The role of NGF in the sensitivity of the rat nervous system to carcinogenesis by ENU and its possible implications in the development of the nervous system are discussed.

Original languageEnglish (US)
Pages (from-to)351-361
Number of pages11
JournalJournal of Neuroscience Research
Volume5
Issue number4
StatePublished - 1980
Externally publishedYes

Fingerprint

Ethylnitrosourea
Nerve Growth Factor
Carcinogenesis
Nervous System
Neurilemmoma
Neoplasms
Nervous System Neoplasms
Trigeminal Nerve
Peripheral Nervous System
Glioma
Pregnancy
Antibodies

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis. / Vinores, S. A.; Perez-Polo, J. R.

In: Journal of Neuroscience Research, Vol. 5, No. 4, 1980, p. 351-361.

Research output: Contribution to journalArticle

Vinores, S. A. ; Perez-Polo, J. R. / Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis. In: Journal of Neuroscience Research. 1980 ; Vol. 5, No. 4. pp. 351-361.
@article{5657135b95d6401ea3bf70fdada13cd0,
title = "Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis",
abstract = "The sensitivity of the rat nervous system to malignant transformation by ethylnitrosourea (ENU) is a function of age at treatment. From late gestation, nervous structures decrease in sensitivity with age as non-neural structures increase in susceptibility. There is a decrease in the proportion of neural tumors induced by ENU and an increase in survival time when nerve growth factor (NGF) levels are elevated in the fetal or neonatal stage. If antibodies directed against mouse beta-NGF (anti-NGF) are administered prior to neonatal ENU treatment, neural tumors appear earlier, although in the same proportion as with treatment by ENU alone. This effect is not observed if the ENU is administered first. This phenomenon seems to be attributed to an increased number of trigeminal nerve neurinomas, which have a shorter latent period than other nervous system tumors. The induced neurological tumors in rats treated neonatally with anti-NGF prior to ENU seem to be almost exclusively neurinomas in the peripheral nervous system. Fetal anti-NGF treatment leads to an increased number of intracerebral gliomas and a longer survival time, which corresponds to the longer latent period of these tumors. The role of NGF in the sensitivity of the rat nervous system to carcinogenesis by ENU and its possible implications in the development of the nervous system are discussed.",
author = "Vinores, {S. A.} and Perez-Polo, {J. R.}",
year = "1980",
language = "English (US)",
volume = "5",
pages = "351--361",
journal = "Journal of Neuroscience Research",
issn = "0360-4012",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Role of nerve growth factor in ethylnitrosourea-induced neural carcinogenesis

AU - Vinores, S. A.

AU - Perez-Polo, J. R.

PY - 1980

Y1 - 1980

N2 - The sensitivity of the rat nervous system to malignant transformation by ethylnitrosourea (ENU) is a function of age at treatment. From late gestation, nervous structures decrease in sensitivity with age as non-neural structures increase in susceptibility. There is a decrease in the proportion of neural tumors induced by ENU and an increase in survival time when nerve growth factor (NGF) levels are elevated in the fetal or neonatal stage. If antibodies directed against mouse beta-NGF (anti-NGF) are administered prior to neonatal ENU treatment, neural tumors appear earlier, although in the same proportion as with treatment by ENU alone. This effect is not observed if the ENU is administered first. This phenomenon seems to be attributed to an increased number of trigeminal nerve neurinomas, which have a shorter latent period than other nervous system tumors. The induced neurological tumors in rats treated neonatally with anti-NGF prior to ENU seem to be almost exclusively neurinomas in the peripheral nervous system. Fetal anti-NGF treatment leads to an increased number of intracerebral gliomas and a longer survival time, which corresponds to the longer latent period of these tumors. The role of NGF in the sensitivity of the rat nervous system to carcinogenesis by ENU and its possible implications in the development of the nervous system are discussed.

AB - The sensitivity of the rat nervous system to malignant transformation by ethylnitrosourea (ENU) is a function of age at treatment. From late gestation, nervous structures decrease in sensitivity with age as non-neural structures increase in susceptibility. There is a decrease in the proportion of neural tumors induced by ENU and an increase in survival time when nerve growth factor (NGF) levels are elevated in the fetal or neonatal stage. If antibodies directed against mouse beta-NGF (anti-NGF) are administered prior to neonatal ENU treatment, neural tumors appear earlier, although in the same proportion as with treatment by ENU alone. This effect is not observed if the ENU is administered first. This phenomenon seems to be attributed to an increased number of trigeminal nerve neurinomas, which have a shorter latent period than other nervous system tumors. The induced neurological tumors in rats treated neonatally with anti-NGF prior to ENU seem to be almost exclusively neurinomas in the peripheral nervous system. Fetal anti-NGF treatment leads to an increased number of intracerebral gliomas and a longer survival time, which corresponds to the longer latent period of these tumors. The role of NGF in the sensitivity of the rat nervous system to carcinogenesis by ENU and its possible implications in the development of the nervous system are discussed.

UR - http://www.scopus.com/inward/record.url?scp=0018961877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018961877&partnerID=8YFLogxK

M3 - Article

C2 - 7431436

AN - SCOPUS:0018961877

VL - 5

SP - 351

EP - 361

JO - Journal of Neuroscience Research

JF - Journal of Neuroscience Research

SN - 0360-4012

IS - 4

ER -